天美传媒

The research interests of Bobbi S. Pritt, M.D., are in clinical parasitology, vector-borne diseases, trainee education, and appropriate test utilization.

As director of the Clinical Parasitology Laboratory in Mayo Clinic's Department of Laboratory Medicine and Pathology, Dr. Pritt has coordinated the development of real-time polymerase chain reaction (PCR) assays for multiple tick and mosquito-borne pathogens such as Plasmodium knowlesi, Borrelia mayonii, Borrelia miyamotoi, Powassan virus and chikungunya virus.

She has also developed a multiplex PCR assay for the major human pathogenic microsporidia species that cause diarrhea and disseminated infections.

Most recently, Dr. Pritt has directed multiple research efforts to characterize two novel tick-borne pathogens that infect humans in the upper midwest region of the United States.

Dr. Pritt's work has resulted in the implementation of rapid and highly sensitive molecular tests for important human infections, including malaria, microsporidiosis, Lyme disease and Borrelia miyamotoi infection. Malaria, in particular, is a potentially fatal disease and a leading cause of infant mortality worldwide. In the U.S., malaria is most commonly seen in individuals who have traveled to or emigrated from endemic areas such as parts of Africa, Asia and South America.

Dr. Pritt also played a key role in discovering and describing two new tick-borne pathogens. In 2011, she described an Ehrlichia muris-like bacterium, and in 2016, she described a novel Borrelia species (Candidatus Borrelia mayonii), which causes Lyme disease. Both pathogens appear to be limited to the upper midwest region of the United States.

Jan Kitajewski, PhD,  is the Director of the University of Illinois Cancer Center and head of the Department of Physiology and Biophysics at the University of Illinois Chicago (UIC).

His research is focused on tumor angiogenesis, cell fate determination, GPCR signaling and pathway remodeling. His specific areas of focus are vessel development, reproductive angiogenesis and tumor angiogenesis associated with breast and ovarian cancer. His lab established that Notch functions in tumor angiogenesis and developed therapeutic strategies to treat gynecological malignancies and breast cancer.

Kitajewski received his PhD from Princeton University. Previously, he served at Columbia University as Co-Director of the Cancer Signaling Networks program at Herbert Irving Comprehensive Cancer Center (HICCC) and Director of the Division of Reproductive Sciences in the Department of Ob/Gyn.

Sergei Iugai, is a ECFMG-certified and GCP-certified researcher in the Surgical Oncology Department of the Institute for Cancer Care at Mercy Medical Center in Baltimore, Maryland, USA. His current area of interest - surgical and medical treatment of Peritoneal Surface Malignancies (PSM).

Sergei Iugai am fully trained and qualified medical oncologist with experience in the field of inpatient and outpatient care of patients with solid tumors and hematological malignancies as well as palliative and supportive care in oncology. He received general medical degree at Saint Petersburg State University, Faculty of Medicine. After graduation he got the residency position in Saint Petersburg Pediatric Medical University (Department of Oncology and Radiology) and also went through 2-year postgraduate educational program 'Higher school of oncology' with 5% acceptance rate. His medical oncology expertise was confirmed by passing European Society of Medical Oncology (ESMO) examination in 2022.